Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA7 | P43166 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA6 | P23280 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490281 | 1.00 | TDP1 (0.78) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL3263647 | 0.90 | TDP1 (0.78) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL21323932 | 0.90 | TDP1 (0.78) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL3262244 | 0.90 | TDP1 (0.78) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL19244175 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL19244383 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL9453997 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL12104057 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL19244230 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 | |
| SCHEMBL19244304 | 0.89 | TDP1 (0.76) | TDP1CA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9176613-A | — | — | None | — | — | JP | disclosed |
| WO-2023080405-A1 | PHOTOALIGNMENT COMPOUND, MANUFACTURING METHOD THEREFOR, LIQUID CRYSTAL PHOTOALIGNMENT AGENT USING SAME, AND RETARDATION FILM COMPRISING SAME | 주식회사 클랩 | 2023-05-11 | — | — | WO | disclosed |
| EP-3166586-B1 | ANHYDROUS OIL BASED ON DELIVERY PARTICLES CONTAINING A BENEFIT AGENT | OREAL (FR) | 2020-04-15 | — | — | EP | disclosed |
| US-10314778-B2 | Anhydrous oil based on particles encapsulating a beneficial agent | L'OREAL (FR) | 2019-06-11 | — | — | US | disclosed |
| US-20170209361-A1 | ANHYDROUS OIL BASED ON PARTICLES ENCAPSULATING A BENEFICIAL AGENT | L'OREAL (FR) | 2017-07-27 | — | — | US | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20090098076-A1 | Method For the Production of a Keratin-Binding Effector Molecule | BASF SE (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| US-5843410-A | Polymeric ultraviolet screening agent and process for the preparation thereof | LG CHEMICAL LTD. (KR) | 1998-12-01 | — | — | US | disclosed |
| JP-H09176613-A | HIGH-MOLECULAR ULTRAVIOLET-SCREENING AGENT AND ITS PRODUCTION | LG CHEM LTD | 1997-07-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | TDP1 1049/4885CA12 3215/4885CA7 1952/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | TDP1 2793/4885CA12 2109/4885CA7 589/4885 |
| US-10314778-B2 | Anhydrous oil based on particles encapsulating a beneficial agent | KRT18, DSG1, EPCAM | TDP1 3516/4885CA12 127/4885CA7 679/4885 |
| US-20170209361-A1 | ANHYDROUS OIL BASED ON PARTICLES ENCAPSULATING A BENEFICIAL AGENT | KRT18, DSG1, EPCAM | TDP1 3516/4885CA12 127/4885CA7 679/4885 |
| US-20090098076-A1 | Method For the Production of a Keratin-Binding Effector Molecule | KRT18, KRTCAP2, CUTA | TDP1 4613/4885CA12 1122/4885CA7 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.